NASDAQ:SNSE

Sensei Biotherapeutics Competitors

$14.13
-0.66 (-4.46 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.01
Now: $14.13
$14.85
50-Day Range
$12.04
MA: $15.61
$19.92
52-Week Range
$11.75
Now: $14.13
$26.50
Volume30,059 shs
Average Volume244,647 shs
Market Capitalization$432.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Sensei Biotherapeutics (NASDAQ:SNSE) Vs. BCAB, IMCR, CGEM, EWTX, KNTE, and SBTX

Should you be buying SNSE stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Sensei Biotherapeutics, including BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX), Kinnate Biopharma (KNTE), and Silverback Therapeutics (SBTX).

BioAtla (NASDAQ:BCAB) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Earnings & Valuation

This table compares BioAtla and Sensei Biotherapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for BioAtla and Sensei Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Sensei Biotherapeutics00403.00

BioAtla presently has a consensus price target of $58.00, suggesting a potential upside of 22.49%. Sensei Biotherapeutics has a consensus price target of $29.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than BioAtla.

Profitability

This table compares BioAtla and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/A

Summary

Sensei Biotherapeutics beats BioAtla on 1 of the 1 factors compared between the two stocks.

Sensei Biotherapeutics (NASDAQ:SNSE) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Sensei Biotherapeutics and Immunocore's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensei BiotherapeuticsN/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Sensei Biotherapeutics and Immunocore, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sensei Biotherapeutics00403.00
Immunocore01202.67

Sensei Biotherapeutics currently has a consensus price target of $29.50, suggesting a potential upside of 108.78%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 53.18%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Immunocore.

Profitability

This table compares Sensei Biotherapeutics and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sensei BiotherapeuticsN/AN/AN/A
ImmunocoreN/AN/AN/A

Summary

Sensei Biotherapeutics beats Immunocore on 3 of the 3 factors compared between the two stocks.

Sensei Biotherapeutics (NASDAQ:SNSE) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Sensei Biotherapeutics and Cullinan Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensei BiotherapeuticsN/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Sensei Biotherapeutics and Cullinan Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sensei Biotherapeutics00403.00
Cullinan Oncology01302.75

Sensei Biotherapeutics currently has a consensus price target of $29.50, suggesting a potential upside of 108.78%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Cullinan Oncology.

Profitability

This table compares Sensei Biotherapeutics and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sensei BiotherapeuticsN/AN/AN/A
Cullinan OncologyN/AN/AN/A

Summary

Sensei Biotherapeutics beats Cullinan Oncology on 3 of the 3 factors compared between the two stocks.

Sensei Biotherapeutics (NASDAQ:SNSE) and Cricut (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Sensei Biotherapeutics and Cricut's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensei BiotherapeuticsN/AN/AN/AN/AN/A
CricutN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Sensei Biotherapeutics and Cricut, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sensei Biotherapeutics00403.00
Cricut0000N/A

Sensei Biotherapeutics currently has a consensus price target of $29.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' higher probable upside, research analysts clearly believe Sensei Biotherapeutics is more favorable than Cricut.

Profitability

This table compares Sensei Biotherapeutics and Cricut's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sensei BiotherapeuticsN/AN/AN/A
CricutN/AN/AN/A

Summary

Sensei Biotherapeutics beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Profitability

This table compares Kinnate Biopharma and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kinnate BiopharmaN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Kinnate Biopharma and Sensei Biotherapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kinnate Biopharma00403.00
Sensei Biotherapeutics00403.00

Kinnate Biopharma currently has a consensus target price of $52.00, suggesting a potential upside of 64.82%. Sensei Biotherapeutics has a consensus target price of $29.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Kinnate Biopharma.

Earnings and Valuation

This table compares Kinnate Biopharma and Sensei Biotherapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kinnate BiopharmaN/AN/AN/AN/AN/A
Sensei BiotherapeuticsN/AN/AN/AN/AN/A

Summary

Sensei Biotherapeutics beats Kinnate Biopharma on 1 of the 1 factors compared between the two stocks.

Sensei Biotherapeutics (NASDAQ:SNSE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Sensei Biotherapeutics and Silverback Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sensei BiotherapeuticsN/AN/AN/A
Silverback TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Sensei Biotherapeutics and Silverback Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sensei Biotherapeutics00403.00
Silverback Therapeutics00403.00

Sensei Biotherapeutics presently has a consensus target price of $29.50, suggesting a potential upside of 108.78%. Silverback Therapeutics has a consensus target price of $50.25, suggesting a potential upside of 31.99%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Silverback Therapeutics.

Valuation & Earnings

This table compares Sensei Biotherapeutics and Silverback Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensei BiotherapeuticsN/AN/AN/AN/AN/A
Silverback TherapeuticsN/AN/AN/AN/AN/A

Summary

Sensei Biotherapeutics beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.


Sensei Biotherapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioAtla logo
BCAB
BioAtla
1.5$47.35-0.7%$1.59 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$35.47-2.3%$1.53 billionN/A0.00Gap Down
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$32.30-5.8%$1.41 billionN/A0.00News Coverage
Gap Down
EWTX
Cricut
0.3$29.54-1.6%$1.41 billionN/A0.00News Coverage
KNTE
Kinnate Biopharma
1.7$31.55-0.5%$1.37 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.07-5.4%$1.33 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.12-9.2%$1.29 billionN/A0.00Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.02-5.2%$1.19 billionN/A0.00Gap Down
FDMT
4D Molecular Therapeutics
1.1$37.69-7.7%$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00-3.5%$948.89 millionN/A0.00News Coverage
Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$27.01-11.1%$948.02 millionN/A0.00Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Down
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32-0.1%$901.71 millionN/A0.00News Coverage
Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50-6.1%$885.10 millionN/A0.00Analyst Downgrade
Gap Down
PHAR
Pharming Group
0.0$13.26-0.0%$845.93 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
FNCH
Finch Therapeutics Group
0.3$17.18-1.9%$809.95 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22-6.1%$568.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$17.76-1.7%$559.32 millionN/A0.00News Coverage
Inventiva logo
IVA
Inventiva
1.4$14.44-2.2%$557.76 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93-2.9%$475.62 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48-1.4%$456.41 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85-2.4%$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93-2.3%$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23-2.0%$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83-1.0%$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07-6.2%$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00-0.0%$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54-0.8%$262.47 millionN/A0.00News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28-5.1%$234.78 millionN/A0.00News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54-0.1%$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98-0.1%$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06-0.9%$156.39 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$6.81-0.4%$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09-9.2%$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64-3.2%$100.92 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.66-6.7%$61.20 millionN/A0.00Gap Down
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62-0.4%$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17-2.3%$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87-1.0%$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66-1.3%$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86-23.5%$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90-19.8%$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Down
VYNT
Vyant Bio
0.0$4.02-4.0%$16.42 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$5.21-15.9%$4.02 millionN/A0.00High Trading Volume
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78-5.3%$0.00N/A0.00Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94-0.7%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00
RPHM
Reneo Pharmaceuticals
0.0$13.89-8.0%$0.00N/A0.00High Trading Volume
Gap Down
SCPS
Scopus BioPharma
1.4$7.57-6.2%$0.00N/A0.00Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.